Journal
FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY
Volume 60, Issue 2, Pages 99-112Publisher
WILEY
DOI: 10.1111/j.1574-695X.2010.00723.x
Keywords
chronic bacterial prostatitis; prostatitis treatment; phage therapy; bacterial biofilm; quinolones
Categories
Funding
- Operational Program Innovative Economy
- [2 P05B 111 30]
- [POIG 01.03.01-02-003/08]
Ask authors/readers for more resources
Chronic bacterial prostatitis (CBP) is a long-lasting and crippling disease that strongly impacts the patient's quality of life. The diagnosis of CBP is difficult and the treatment regimens are not always successful. Poor penetration of antibiotics to the prostate tissue, the drug resistance of uropathogens, the adverse events associated with antibiotic treatment, the persistence of prostatic calculi, and biofilm formation in the prostate gland are factors that contribute toward decreasing the cure rate of CBP. The phenomenon of increasing antibiotic resistance, which has also been called a clinical super-challenge, has revived interest in therapy using bacterial viruses (bacteriophages or phages). Because of their mechanism of action, which is completely different from those of all antibiotics, phages are effective even against multidrug-resistant bacteria. Here, we describe the current perspectives on the possible application of phage therapy (PT) in treating CBP. The advantages of therapeutic phages, including their interactions with bacterial biofilm, as well as the safety of PT are discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available